Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
The Hidden Link between Racism and Alzheimer’s Risk
Dr. Andrea Rosso and Dr. Beth Shaaban shared their expertise with Scientific American on how Racial Discrimination can be linked to higher risks of an Alzheimer's diagnosis. The article, published by journalist Jyoti Madhusoodanan, can be found in How Racial...
